Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs Transcript

Core Points - Neumora is conducting a presentation in lieu of its formal earnings call for the quarter [2] - The company plans to report its third quarter 2025 financial results on November 6, with a press release available on its Investor Relations website [2] Group 1 - The presentation includes forward-looking statements based on current expectations and beliefs [2] - Key members of Neumora's management team are present, including CEO Paul Berns and other executives [3]